Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $44 to $36.